Kardigan, Inc. (KARD) Stock Price & How to Invest
Short answer
KARD is Kardigan, a clinical-stage precision cardiovascular biotech that went public on Nasdaq in June 2026, so investing in it is a bet on unproven heart-disease drug candidates rather than current profits or revenue. It suits only investors comfortable with binary, pre-commercial biotech risk.
KARD stock price
As of 2026-07-09, Kardigan, Inc. (KARD) last closed at $24.45. Over its trading history so far it has traded between $22.00 and $25.90.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Kardigan, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Kardigan, Inc. (KARD) do?
Kardigan, Inc. (Nasdaq: KARD) is a clinical-stage precision cardiovascular therapeutics company based in Princeton, New Jersey, founded in 2023 and formerly known as EnCarda. It was created by former executives of MyoKardia, the team behind mavacamten (Camzyos), the hypertrophic cardiomyopathy drug that led to Bristol Myers Squibb's roughly $13 billion acquisition of MyoKardia. Kardigan is developing three late-stage candidates that target the underlying biology of specific heart conditions where treatments are limited: danicamtiv (a cardiac myosin activator in-licensed from BMS) for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. It pairs these programs with the Prolaio AI and real-world-data platform, branded as Cardiac Intelligence, to sharpen trial design.
The investment picture is a classic pre-commercial biotech profile. Kardigan has no product revenue and reported a net loss of roughly $192 million for 2025 and about $56 million for the first quarter of 2026, with an accumulated deficit near $337 million. Its June 2026 IPO priced 25 million shares at $16.00 and raised over $400 million in gross proceeds (about $460 million with the full overallotment), giving a market capitalization of roughly $2 billion and a cash runway that management expects to fund operations into 2028. Value here is driven almost entirely by clinical data, not financial results, with the most important trial readouts expected around 2027.
What's driving Kardigan, Inc. (KARD)?
1. Late-stage cardiovascular pipeline
Kardigan carries three programs already in Phase 2b or Phase 2b/3, which is unusually advanced for a company this young. Danicamtiv, ataciguat, and tonlamarsen each target a heart condition with limited or no approved disease-modifying therapy, so positive data could address large unmet needs. The trade-off is that all three still face the standard risk that mid- or late-stage trials miss their endpoints.
2. MyoKardia pedigree and BMS-sourced asset
The founding team previously developed and won approval for mavacamten at MyoKardia, giving Kardigan credibility in cardiac drug development. Danicamtiv was originally discovered at MyoKardia and advanced by Bristol Myers Squibb before Kardigan in-licensed worldwide rights. That track record helped attract a large IPO, though past success does not guarantee that these specific molecules will succeed.
3. Well-funded runway into 2028
With over $400 million of fresh IPO proceeds on top of roughly $287 million of pre-IPO cash, Kardigan says it is funded into 2028, past several expected catalyst readouts. A funded runway reduces near-term financing pressure, but continued spending and future trials mean additional capital raises (and potential dilution) are likely before any product reaches market.
4. AI and real-world-data platform
The Prolaio-based Cardiac Intelligence platform is positioned to use real-world patient data and analytics to inform trial design and patient selection. If it shortens or de-risks development, it could be a differentiator against traditional cardiovascular developers. For now it is a supporting tool, and its impact on actual approval odds is unproven.
What are the risks to Kardigan, Inc. (KARD)?
Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. Its S-1 disclosures included going-concern language tied to pre-IPO cash, and while the IPO extended the runway into 2028, the company will likely need to raise more capital and could dilute shareholders. Any negative or delayed data from danicamtiv, ataciguat, or tonlamarsen could sharply reduce the stock, and a post-IPO lock-up expiration may add selling pressure. As a brand-new listing with a roughly $2 billion valuation against no earnings, the shares can be highly volatile. It also competes with larger, better-capitalized cardiovascular players.
How is Kardigan, Inc. (KARD) valued? (approximate, Q1 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kardigan, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$0 (pre-commercial)
- Net loss (TTM): ~-$230M
- Net loss (Q1 2026): ~-$56M
- Cash & investments (pre-IPO): ~$287M
- IPO gross proceeds (Jun 2026): ~$400M+
- Market cap: ~$2.0B
Kardigan generates no product revenue and funds a large research budget, producing net losses near $56 million in Q1 2026 and roughly $192 million for full-year 2025. Its valuation reflects pipeline potential, not current financials, and the roughly $2 billion market cap sits against zero sales. The IPO and prior cash give a runway management expects to last into 2028.
Who competes with Kardigan, Inc. (KARD)?
Precision cardiovascular biotechs
Companies such as Cytokinetics, BridgeBio, and Tenaya Therapeutics also target genetic and structural heart diseases with novel mechanisms. They compete with Kardigan for trial patients, talent, and investor capital, and some have programs aimed at overlapping indications like cardiomyopathy.
Large-cap pharma in cardiology
Bristol Myers Squibb (which markets Camzyos and out-licensed danicamtiv), Novartis, and AstraZeneca have deep cardiovascular franchises and resources. Their approved or late-stage therapies set the bar Kardigan's candidates must clear and could reach adjacent patient populations first.
Device and procedural alternatives
For calcific aortic valve stenosis, procedural options such as transcatheter aortic valve replacement from Edwards Lifesciences and Medtronic already exist. A drug like ataciguat must show it can meaningfully slow disease in patients who might otherwise be managed with monitoring or eventual valve replacement.
How to invest in Kardigan, Inc. (KARD)
There are three common ways to get KARD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so KARD sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where KARD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Kardigan, Inc. (KARD)
Kardigan is a well-funded, pedigreed clinical-stage cardiovascular biotech whose value hinges entirely on trial readouts that are still years away.
More on Kardigan, Inc. (KARD)
Whether KARD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KARD a buy?, and where the stock could go from here in the KARD stock forecast.
For income investors, whether KARD pays a dividend and how the payout looks is covered in does KARD pay a dividend?
Build a basket around KARD with Walnut
Use Kardigan, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What company is stock ticker KARD?
+
KARD is Kardigan, Inc., a clinical-stage precision cardiovascular therapeutics company that trades on the Nasdaq Global Market. It develops medicines aimed at the underlying biology of specific heart diseases and is based in Princeton, New Jersey.
When did Kardigan go public?
+
Kardigan began trading on Nasdaq on June 18, 2026. It priced its upsized IPO at $16.00 per share for 25 million shares, raising over $400 million in gross proceeds (about $460 million with the full overallotment exercised).
Does Kardigan have any revenue or approved products?
+
No. Kardigan is pre-commercial with no product revenue and no approved drugs. Its three candidates are still in clinical trials, so the company reports net losses and depends on outside capital rather than sales.
What drugs is Kardigan developing?
+
Its three late-stage candidates are danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. Danicamtiv was originally discovered at MyoKardia and later advanced by Bristol Myers Squibb before Kardigan licensed it.
Who founded Kardigan?
+
Kardigan was founded in 2023 (originally as EnCarda) by former executives of MyoKardia, the team that developed mavacamten (Camzyos). MyoKardia was acquired by Bristol Myers Squibb for roughly $13 billion, giving the founders a notable cardiovascular track record.
How much cash does Kardigan have?
+
Kardigan reported about $287 million in cash and investments as of March 31, 2026, before its IPO. Adding more than $400 million of IPO proceeds, management expects the combined cash to fund operations into 2028, though further raises are likely.
Why is Kardigan considered high risk?
+
It is a pre-revenue biotech whose value rests on trial outcomes that are still years away and could fail. Its S-1 carried going-concern language tied to pre-IPO cash, it may need more capital, and as a brand-new listing near a $2 billion valuation with no earnings, the shares can be very volatile.
When are Kardigan's key trial results expected?
+
The most important data readouts from Kardigan's Phase 2b and Phase 2b/3 programs are generally expected around 2027. Those results would be the main catalysts that determine whether the candidates advance toward potential approval, and they carry meaningful binary risk.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Kardigan, Inc.'s investor relations page or your broker before making investment decisions.